Dastani Mostafa, Rahimi Hamid Reza, Askari Vahid Reza, Jaafari Mahmoud Reza, Jarahi Lida, Yadollahi Asal, Rahimi Vafa Baradaran
Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Vascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Biofactors. 2023 Jan;49(1):108-118. doi: 10.1002/biof.1874. Epub 2022 Jun 8.
Diabetes is one of the most common chronic diseases worldwide. Systemic inflammation (high-sensitivity C-reactive protein (hs-CRP)) and lipid metabolism disruption (lipoprotein A, LipoPr (a)) play a critical role in developing and progressing atherosclerosis and acute coronary syndrome in diabetic patients. The anti-oxidant and anti-inflammatory effects of curcumin have been emphasized previously. Therefore, we aimed to evaluate the impact of nano-curcumin on cardiovascular risk factors in type 2 diabetic patients with mild to moderate coronary artery disease (CAD). We performed a randomized, double-blinded, placebo-controlled clinical trial with type 2 diabetic patients (n = 64), and mild to moderate CAD (<70% stenosis in angiography). The patients received nano-curcumin (80 mg/day) or placebo along with optimal medications for 90 days. The biofactors, including hs-CRP and LipoPr (a), and lipid profile, were measured at the admission of patients and end of the study. Nano-curcumin significantly mitigated the hs-CRP and LipoPr (a) levels following 90 days of treatment (P < 0.001 and P = 0.043, respectively). In addition, the mean percentage of change (%Δ) in the hs-CRP and LipoPr (a) levels were meaningfully reduced in the nano-curcumin group compared to the placebo group (P < 0.001 and P = 0.007, respectively). Surprisingly, nano-curcumin notably propagated the number of patients with mild (34.35%) and moderate (62.5%) hs-CRP level category and strikingly diminished the number of patients with severe hs-CRP level category (3.125%) compared to the placebo group (P = 0.016). Nano-curcumin (80 mg/day) might prevent atherosclerosis progression and, in terms of attenuating hs-CRP levels as an inflammation index, succedent cardiovascular events in diabetic heart patients.
糖尿病是全球最常见的慢性疾病之一。全身炎症反应（高敏C反应蛋白（hs-CRP））和脂质代谢紊乱（脂蛋白A，LipoPr（a））在糖尿病患者动脉粥样硬化的发生和发展以及急性冠状动脉综合征中起关键作用。姜黄素的抗氧化和抗炎作用此前已得到强调。因此，我们旨在评估纳米姜黄素对轻度至中度冠状动脉疾病（CAD）的2型糖尿病患者心血管危险因素的影响。我们对64例2型糖尿病且患有轻度至中度CAD（血管造影狭窄<70%）的患者进行了一项随机、双盲、安慰剂对照临床试验。患者接受纳米姜黄素（80毫克/天）或安慰剂，并同时服用最佳药物，为期90天。在患者入院时和研究结束时测量生物因子，包括hs-CRP和LipoPr（a）以及血脂谱。治疗90天后，纳米姜黄素显著降低了hs-CRP和LipoPr（a）水平（分别为P < 0.001和P = 0.043）。此外，与安慰剂组相比，纳米姜黄素组hs-CRP和LipoPr（a）水平的平均变化百分比（%Δ）显著降低（分别为P < 0.001和P = 0.007）。令人惊讶的是，与安慰剂组相比，纳米姜黄素显著增加了轻度（34.35%）和中度（62.5%）hs-CRP水平类别的患者数量，并显著减少了重度hs-CRP水平类别的患者数量（3.125%）（P = 0.016）。纳米姜黄素（80毫克/天）可能会阻止动脉粥样硬化的进展，并且就降低作为炎症指标的hs-CRP水平而言，可预防糖尿病心脏患者随后发生的心血管事件。
